772-79-2

Basic information

• Product Name: 4-CHLOROPHENYL PHOSPHORODICHLORIDATE
• Synonyms: 4-CHLOROPHENYL DICHLOROPHOSPHATE;4-CHLOROPHENYL PHOSPHORODICHLORIDATE;4-CHLOROPHENYLPHOSPHORYL DICHLORIDE;4-Chlorophenyl dichloridophosphate;4-chlorophenyl phosphonodichloridate;p-chlorophenyl dichlorophosphate;4-Chlorophenyl phosphorodichloridate, 98+%;4-Chlorophenyl dichlorophosphate, 98+%
• CAS NO: 772-79-2
• Molecular Formula: C₆H₄Cl₃O₂P
• Molecular Weight: 245.43
• EINECS: 212-254-1
• Product Categories: Biochemistry;Nucleosides, Nucleotides & Related Reagents;Phosphorylating and Phosphorothioating Agents;Phosphorylation;Protecting Agents, Phosphorylating Agents & Condensing Agents;Synthetic Organic Chemistry
• Mol File: 772-79-2.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 142 °C11 mm Hg(lit.)
• Flash Point: 223 °F
• Appearance: Clear colorless/Liquid
• Density: 1.508 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00576mmHg at 25°C
• Refractive Index: n20/D 1.539(lit.)
• Storage Temp.: Store at 0-5°C
• Water Solubility: Reacts with water.
• Sensitive: Moisture Sensitive
• BRN: 910754
• CAS DataBase Reference: 4-CHLOROPHENYL PHOSPHORODICHLORIDATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROPHENYL PHOSPHORODICHLORIDATE(772-79-2)
• EPA Substance Registry System: 4-CHLOROPHENYL PHOSPHORODICHLORIDATE(772-79-2)

Safety Data

• Hazard Codes: C
• Statements: 14-34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• F: 10
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 772-79-2(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless liquid

Uses

4-Chlorophenyl phosphorodichloridate is used as phosphorylation agent. Reactant for preparation of antimicrobial agents, antioxidant agents, antitumor agents, nucleotide anti-viral prodrug.

InChI:InChI=1/C6H4Cl3O2P/c7-5-1-3-6(4-2-5)11-12(8,9)10/h1-4H

Upstream product

• 106-48-9 4-chloro-phenol 
• 98-67-9 p-hydoroxybenzenesulfonic acid 
• 10026-13-8 phosphorus pentachloride 
• 871896-25-2 4-dichlorophosphoryloxy-benzenesulfonyl chloride 
• 13388-88-0 4-chlorophenyl phosphate 

Downstream Products

• 81265-94-3 5'-dimethoxytrityl 2'-tert-butyldimethyl silyl uridine 3'-p-chlorophenyl β-cyanoethyl phosphotriester 
• 82444-82-4 4-(1,2,4-triazol-1-yl)-1-<5'-O-(dimethoxytrityl)-3'-O-((p-chlorophenoxy)(2-cyanoethoxy)phosphoryl)-2'-O-(tert-butyldimetylsilyl)-β-D-ribofuranosyl>pyrimidin-2-(1H)-one 
• 62420-37-5 (p-chlorophenyl) di(1,2,4-triazolido)phosphate 
• 69497-44-5 p-chlorophenyl N-phenylphosphoramidochloridate 
• 144230-64-8 2-(4-Chloro-phenoxy)-6-ethyl-[1,3,6,2]dioxazaphosphonane 2-oxide 
• 116454-16-1 C₄₉H₄₆Cl₂N₈O₁₆P₂*C₆H₁₅N 
• 100032-49-3 3-(4-chlorophenoxy)-1,5-dihydro-7,8-dimethyl-2,4,3-benzodithiaphosphepon 3-oxide 
• 105053-54-1 6-(4-Chloro-phenoxy)-5,7-dioxa-6-phospha-dibenzo[a,c]cycloheptene 6-oxide 
• 138650-18-7 2,10-dichloro-6-(4-chlorophenoxy)-12H-dibenzo<1,3,2>-dioxaphosphocin 6-oxide 
• 137734-75-9 C₂₇H₁₈ClO₄P 
• 120643-14-3 2-(4-chlorphenyloxy)-3-cyclohexyl-6-(1,1-dimethylethyl)-3,4-dihydro-2H-1,3,2-benzoxazaphosphorine-2-oxide 
• 71100-63-5 C₄₁H₄₀ClN₅O₁₀P^(1-) 
• 71065-98-0 4-chlorophenyl 5'-O-(4,4'-dimethoxytrityl)-N²-isobutyryl-2'-deoxyguanosin-3'-yl phosphate 
• 86359-83-3 (MeO)TrdT<*>dTp(ClPh) 

Relevant articles and documents

Prodrug compound and application ofprodrug compound in treatment of cancer

The present invention provides a compound indicated by a formula (I), pharmaceutically acceptable salts or esters thereof, a pharmaceutical composition of the compound, and application of the compoundand the pharmaceutical composition in the inhibition or regulation of the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.

A convenient solid phase approach to obtain lipophilic 5′-phosphoramidate derivatives of DNA and RNA oligonucleotides

This paper explores the potential of a modified phosphotriester approach to the synthesis of 5′-phosphoramidate derivatives of DNA and RNA oligonucleotides. The modification of 5′-deprotected support-bound oligonucleotides is done in two steps: i) conversion of the 5′-OH group of an oligonucleotide into an activated phosphodiester, and ii) treatment of the activated phosphodiester with an aminocompound. The approach is efficient and compatible with conventional solid phase oligonucleotide synthesis. It can be used for the conjugation of therapeutically relevant oligonucleotides with functional moieties or carrier constructions, which are to be removed after endocytosis.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.